IBM Stock Gains Amid Plan To Invest $10B For Large-Scale Quantum Computer By 2029

According to IBM’s SEC disclosure, the company has deployed more than 90 quantum systems globally.
The IBM logo appears on a smartphone screen, and a stock exchange curve chart displays as the background. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)
The IBM logo appears on a smartphone screen, and a stock exchange curve chart displays as the background. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)
Profile Image
Shashank Nayar·Stocktwits
Updated May 28, 2026   |   4:32 PM EDT
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • Last week, IBM was among a handful of quantum developers set to receive $2 billion U.S. government funding. 
  • Investment announcement follows a Letter of Intent between IBM and the U.S. Department of Commerce to establish Anderon. 
  • 13 out of 21 analysts rate the stock ‘buy’, seven say ‘hold’, one ‘sell’.

International Business Machines Corp (IBM) share price rose 3% on Thursday after the firm unveiled an aggressive plan to spend more than $10 billion over the next five years on quantum computing, aiming to bring a commercial, large-scale system to market by 2029.

The investment, detailed in a Securities and Exchange Commission filing, will be distributed across research and development, capital expenditures, manufacturing expansion, and targeted corporate acquisitions. The multi-billion-dollar push is aimed at engineering a "fault-tolerant" quantum computer—a milestone that means the hardware can automatically correct its own computational errors, a major hurdle that has long prevented the technology from achieving widespread commercial application.

Read Next
Loading...
Loading...

The tech giant, which already operates more than 90 quantum installations globally, plans to deploy a machine capable of executing 100 million quantum gate operations. If successful, the computing power would easily eclipse standard supercomputers, enabling complex calculations faster than traditional systems.

IBM’s Federal Funding Infusion 

IBM's $10 billion spending plan arrives precisely one week after the federal government signaled a major strategic pivot toward the quantum sector.

On May 21, the Trump administration announced a historic $2 billion federal grant package distributed among nine quantum technology firms. Financed through the 2022 CHIPS and Science Act, the initiative marks a highly unconventional shift in U.S. industrial policy where the Department of Commerce is securing minority equity stakes in the private firms.

Commerce Secretary Howard Lutnick characterized the move as a protective measure to ensure American dominance in national security and advanced research, stating that the administration is "leading the world into a new era of American innovation."

IBM captured half of that federal package, securing a $1 billion grant. The company is matching the government funds with $1 billion of its own capital to establish Anderon, a new subsidiary based in Albany, New York. Anderon will operate as the nation's first purpose-built, pure-play quantum semiconductor foundry, focusing exclusively on manufacturing specialized superconducting wafers.

Other prominent developers—including D-Wave Quantum, Rigetti Computing, IonQ, Atom Computing, Infleqtion, PsiQuantum, and Quantinuum—were awarded letters of intent for individual grants, mostly valued at $100 million each.

IBM Retail View 

Retail sentiment on Stocktwits was “extremely bullish” with “extremely high” message volumes. 

One user highlighted that IBM was ahead of the curve with its quantum computing commitments. 

IBM stock has gained 3% over the past 12 months. 

Read More: OTLK Stock Rocket Nearly 140%: FDA's Lytenava Approval Pushes Stock On Track For Best Week On Record

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Follow on Google News
Read about our editorial guidelines and ethics policy